drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody), intravenous
drug_description
EU-licensed ocrelizumab, a humanized IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent and complement-dependent cytotoxicity and induces apoptosis; plasma cells are spared. Administered intravenously.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ocrelizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti‑CD20 monoclonal antibody that binds CD20 on pre‑B to mature B cells, depleting them via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis; plasma cells (CD20−) are spared, reducing antigen presentation and pro‑inflammatory cytokine signaling.
drug_name
EU-Ocrevus (ocrelizumab)
nct_id_drug_ref
NCT05906992